Asco 2018: Latest Developments In Non-Metastatic & Metastatic Castration-Resistant Prostate Cancer

ASCO 2018: Latest Developments in Non-Metastatic & Metastatic Castration-Resistant Prostate Cancer

Focus on non-metastatic castration resistant prostate cancer

Key Developments in Non-Metastatic & Metastatic Hormone-Sensitive Prostate Cancer

Updates on non-metastatic castration-resistant prostate cancer

ASCO 2018: Novel treatment strategies in prostate cancer therapeutics

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer (CRPC)

Initial Management of Non-Castrate Advanced, Recurrent, or Metastatic Prostate Cancer Guideline U...

Prostate cancer updates from ASCO 2018

Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: ASCO 2018 GU Highlights (BMIC-055)

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

ASCO20 - PROSPER Trial Data - Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

HPR

Updates in kidney cancer to look out for at ASCO 2024

Enzalutamide in the Context of Nonmetastatic CRPC

The Power and Promise of Cancer Research: Presented at ASCO Annual Meeting 2018

National Cancer Institute

Dr. Glimcher on the Latest and Greatest from ASCO 2018

Biotechnology Innovation Organization

Is More Better with Radium-223 for Metastatic Prostate Cancer? ASCO 2018 GU Highlights (BMIC-056)

Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Bladder TCC: ASCO 2018 Highlights (BMIC-049)

ASCO GU 2018: A New Prognostic Model for Urothelial Carcinoma

Report Back from ASCO: What's the Latest in Metastatic Breast Cancer?

SHARE Cancer Support

New PARP Inhibitor Abiraterone Combo in Met Prostate Cancer: ASCO 2018 GU Highlights (BMIC-058)